Clinical trial • Phase I/II • Oncology

PARP inhibitor for Fallopian tube cancer | Ovarian cancer | Extraovarian cancer

Phase I/II trial of PARP inhibitor for Fallopian tube cancer | Ovarian cancer | Extraovarian cancer. 55 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Fallopian tube cancer | Ovarian cancer | Extraovarian cancer
Trial Stage
Phase I/II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
11-12-2024
First CTIS Authorization Date
07-04-2025

Trial design

Phase I/II trial across 1 site in Netherlands.

Target Sample Size
55

Recruitment

Planned Sample Size
55
Recruitment Window Months
109

Geography

Total Number Of Sites
1
Total Number Of Participants
55

Netherlands

Earliest CTIS Part Ii Submission Date
18-03-2025
Latest Decision Or Authorization Date
07-04-2025
Processing Time Days
20
Number Of Sites
1
Number Of Participants
55

Sites

Site Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Department Name
Gynaecologic Oncology
Principal Investigator Name
Willemien van Driel
Principal Investigator Email
w.v.driel@nki.nl
Contact Person Name
Willemien van Driel
Contact Person Email
w.v.driel@nki.nl

Sponsor

Primary sponsor

Full Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Investigational products

Investigational Product Name
PARP inhibitor
Active Substance
PARP inhibitor
Modality
Small molecule
Investigational Product Name
Cisplatin (HIPEC)
Active Substance
Cisplatin
Modality
Small molecule
Routes Of Administration
Intraperitoneal (HIPEC)
Route
Intraperitoneal
Combination Treatment
Yes

Related trials

Other published trials that may interest you.